EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists

Alexandra Flynn iD, Peter Galettis, Howard Gurney, Michael Michael, Ingrid Desar, Kim Westerdijk, Jennifer Schneider, Jennifer Martin

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Alexandra Flynn und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Newcastle, Newcastle, New South Wales, Australia. Hauptthemen laut MEDLINE: Drug Monitoring, Antineoplastic Agents, Oncologists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NSW Cancer Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the development of anticancer agents for solid tumours, body surface area continues to be used to personalise dosing despite minimal evidence for its use over other dosing strategies. With the development of tyrosine kinase inhibitors and other oral targeted anticancer agents, dosing using therapeutic drug monitoring (TDM) is now utilised in many health systems but has had limited uptake in Australia.

Aim

To determine attitudes and barriers to the implementation of TDM among Australian oncologists.

Methods

A comprehensive questionnaire was developed by the Dutch Pharmacology Oncology Group from semistructured interviews of stakeholders. Seventy‐nine questions across seven domains were developed with three free‐text responses. This was rationalised to 17 questions with three free‐text responses for Australian medical oncologists who identified limited experience with TDM.

Results

Fifty‐seven responses were received, with 49 clinicians (86%) identifying limited experience of performing TDM in daily practice. Clinicians were positive (62–91% agree/strongly agree across seven questions) about the advantages of TDM. There was a mixed response for cost‐effectiveness and scientific evidence being a barrier to implementation, but strong agreement that prospective studies were needed (75% agreed or strongly agreed); that national treatment guidelines would enable practice (80%) and that a ‘pharmacology of oncolytics’ education programme would be useful (96%) to provide knowledge for dose individualisation.

Conclusion

Despite the limited experience of TDM in oncology in Australia, medical oncologists appear positive about the potential benefit to their patients. We have identified three barriers to implementation that could be targeted for increased adoption of TDM in oncology in Australia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringAntineoplastic AgentsOncologistsHumansAustraliaSurveys and QuestionnairesAttitude of Health PersonnelNeoplasmsMedical Oncology

Stichwörter der Autor:innen

clinical pharmacologyimplementation toolsmedical oncologytherapeutic drug monitoring

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • University of Newcastle, Newcastle, New South Wales, Australia.
  • Macquarie University Hospital, Sydney, New South Wales, Australia.
  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Radboud University Medical Centre, Nijmegen, the Netherlands.

ORCID-Profile: Alexandra Flynn

Förderung

  • NSW Cancer Council

Zitieren

APA

Flynn, A., Galettis, P., Gurney, H., Michael, M., Desar, I., Westerdijk, K., Schneider, J., & Martin, J. (2024). Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists. Internal Medicine Journal. https://doi.org/10.1111/imj.16415

Vancouver

Flynn A, Galettis P, Gurney H, Michael M, Desar I, Westerdijk K, et al. Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists. Internal Medicine Journal. 2024. doi:10.1111/imj.16415

BibTeX
@article{Flynn2024,
  author = {Flynn, Alexandra and Galettis, Peter and Gurney, Howard and Michael, Michael and Desar, Ingrid and Westerdijk, Kim and Schneider, Jennifer and Martin, Jennifer},
  title = {Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16415}
}
Kostenlos starten →